Efficacy of variopeptyle in treating MPCa
Phase 2
- Conditions
- prostate cancer.Malignant neoplasm of prostate
- Registration Number
- IRCT201410289819N5
- Lead Sponsor
- Vice chancellor for research Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 47
Inclusion Criteria
Inclusion Criteria: All patients with metastatic prostate cancer without age limitation who are referred to urology clinic of Imam Khomeyni Hospital, Filling consent form and Not receiving hormone therapy before
Exclusion Criteria:1. dysfunction in Hypothalamic - pituitary - gonadal axis 2. Simultaneous presence of active malignancy with different origin 3. Require the other treatments (chemotherapy, radiotherapy) 4.Inability to obtain consent due to dissatisfaction or intellectual problems
5. History of hypersensitivity to GnRH, GnRH analogs 6. History of bilateral orchiectomy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Testostrone. Timepoint: Before intervention, one month after intervention, three months after intervention and six months after intervention. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method PSA. Timepoint: Before intervention, one month after intervention, three months after intervention and six months after intervention. Method of measurement: ELISA.